All Posts:triple-negative breast cancer
-
ISPY2: A Unique, Flexible Breast Cancer Trial for Modern Times
The ISPY2 breast cancer clinical trial is a unique phase 2 study that offers a broad range of treatment options for patients with locally advanced breast cancer.
Category: Lombardi Stories
-
Biology Behind New Drug Used to Treat Triple-Negative Breast Cancer Uncovered
How TTP488 (azeliragon), an experimental drug, impairs aggressive, triple-negative breast cancer from metastasizing has been uncovered at the cellular level, according to researchers at Georgetown University’s Lombardi Comprehensive Cancer Center.
Category: News Release
-
Clinical Trial Result Leads to New Treatment Option for Hard-to-Treat Breast Cancer
(June 4, 2021) — A clinical trial exploring a new treatment for breast cancer found that women with a hard-to-treat form of the disease lived longer without the disease coming back following treatment. The trial was conducted at sites around the world, including Georgetown Lombardi Comprehensive Cancer Center. “This finding represents a significant step forward […]
Category: Lombardi Stories
-
Glynda’s Story: A Chance to Advance Treatment for Aggressive Cancer
(January 11, 2021) — Inspired by the kindness, proficiency and dedication of her health care team at Georgetown Lombardi Comprehensive Cancer Center, Glynda Brown, a 52-year-old Maryland resident, felt determined to “pay it forward” and make a positive difference for future patients by participating in a clinical trial after she was diagnosed with triple-negative breast […]
Category: Lombardi Stories